NEW YORK (GenomeWeb News) – Drug developer Covance and Rules-Based Medicine have struck a biomarker alliance and services agreement, Covance said today.

Under the pact, RBM will serve as Covance's exclusive third-party provider of multiplexed biomarker testing services, and Covance will serve as RBM's exclusive referral source for lab testing services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.